June 20, 2019: Housing stability and HIV viremia; how the stigma of poverty affects viral load; the best time to employ syringe services; promise for the practice of index testing.
Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.
Epidemiologists are using a combination of molecular surveillance and tuberculosis-style contact tracing in hopes of helping local health departments curb HIV transmissions.
April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
Health care providers often believe stereotypes that PWID are irresponsible and won't adhere to PrEP, according to data presented at the 2019 National HIV Prevention Conference.
Although people living with HIV who "party and play" appear more likely to struggle with treatment adherence, new research suggests that concern does not apply to PrEP.
"Placing more attention on meeting the sexual health and holistic wellness needs of gay men affected by sexualized substance use is critical," writes the associate director of Ontario's Gay Men's Sexual Health Alliance.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
After years of anecdotes and speculation, harm reduction and pharma watchdog advocates have data to back claims that the spike in opioid deaths in the U.S. can be tied to pharmaceutical companies marketing highly addictive opioids to doctors.